AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05986578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham iTBS
Description: Sham TMS will be delivered with the sham side of the MagVenture Cool B70 A/P coil. The software will be pre-programmed by a staff member that will not be involved in data analysis or collection for blinding purposes. The sham stimulation will match the number of pulses and length of time as the active condition and each participant will receive 3 sessions with a 15-20 min interval between sessions.
Study NCT05064878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 (Fenfluramine Hydrochloride)
Description: ZX008 is supplied as an oral aqueous solution of Fenfluramine Hydrochloride.
Study NCT05064878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching ZX008 Placebo
Description: Matching ZX008 placebo is supplied as an oral solution.
Study NCT05969964 — intervention group
Intervention type: BEHAVIORAL
Intervention: Avoid second resection after initial complete resection
Description: Those patients diagnosed with pT1 after initial ERBT with negative vertical and horizontal safety margins won't undergo second look as endorsed by the guidelines.
Study NCT05705193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroFlex (computerized gamified tasks)
Description: The computerized cognitive remediation intervention (NeuroFlex) consists of a series of gamified tasks (e.g., BrainHQ, Neurogrow, Ultimate Word Master) administered via computer tablet. The intervention provides both bottom up training to improve basic processing of sensory stimuli and top down training to improve executive functions. Participants will be asked to complete approximately 7.5 hours a week of computer treatment over an approximately 6-week period, for a total of approximately 45 hours of treatment. The treatment will be completed remotely by the participant within their own home or other private location that is most convenient for the participant.
Study NCT04131647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Maintenance
Description: Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
Study NCT04131647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Maintenance + Intermittent Fasting
Description: Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
Study NCT05280769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral nicotine pouch - 2 mg
Description: On brand oral nicotine pouch with 2 mg of protonated nicotine in original flavor
Study NCT05280769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral nicotine pouch - 4 mg
Description: On brand oral nicotine pouch with 4 mg of protonated nicotine in original flavor
Study NCT05280769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral nicotine pouch - 8 mg
Description: On brand oral nicotine pouch with 8 mg of protonated nicotine in original flavor
Study NCT05280769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco
Description: Participant's typical brand of smokeless tobacco
Study NCT06284486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT06284486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Given by PO
Study NCT06532656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food
Study NCT06532656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/LEN FDC
Description: Tablets administered orally without regard to food
Study NCT06311084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaginator 2.0
Description: Blended psychological digital intervention, combining Functional Imagery Training, a psychological intervention based on CBT and motivational interviewing principles, and a smartphone app.
Study NCT00460720 — intervention group
Intervention type: OTHER
Intervention: Observational treatment compliance survey
Description: Observational treatment compliance survey
Study NCT05164133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive intravenous (IV) tocilizumab
Study NCT06366464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant tablet
Description: Pitolisant tablet
Study NCT06366464 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pitolisant tablet
Description: Pitolisant tablet
Study NCT06366464 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet
Study NCT05118776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40 tablets
Description: ASC40 tablets administered orally once daily
Study NCT05118776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Placebo administered orally once daily.
Study NCT05970302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine
Description: Use the above medications on a regular basis.
Study NCT04667364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Conventional TENS will be performed using two electrodes placed on the involved extremity and with the following stimulation parameters; a frequency of 100 Hz, pulse duration 50-100 ms, and at an intensity gradually increased until the patient feels a strong, tolerable and non-painful sensation (18, 19). The intensity is incrementally increased based on patient feedback. Patients will receive guidelines on how to use the TENS device at home and will over a period of 30 days self-administer TENS as needed. Patients is to fill out a predefined schedule on paper each day to monitor dose.
Study NCT05840250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring and Education Support
Description: Participants will be provided with a device to monitor their blood glucose (Abbott Free Style Libre2 Flash CGM system) along with educational materials to better understand and manage their diabetes and other supporting services. Pre and post intervention surveys will be implemented. Participants will be closely monitored for 3 months and then followed up for 3 more months for a total of 6-month participation.
Study NCT05118776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab once every 2 weeks, intravenous drip.
Study NCT05118776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab once every 2 weeks, intravenous drip.
Study NCT06159491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will take Pacritinib 100 mg - 200mg BID for each 28 day cycle
Study NCT06159491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m\^2 will be administered IV or SQ QD D1-7 of each 28 day cycle
Study NCT04773210 — intervention group
Intervention type: DEVICE
Intervention: Mini tube system
Description: Mini tube system (FLOW-JAC System, Bogotá, Colombia) orthodontic treatment
Study NCT04773210 — intervention group
Intervention type: DEVICE
Intervention: Conventional ligating brackets
Description: Conventional ligating brackets (Gemini 3M Unitek Orthodontic Products bracket, Calif, USA) with Nitinol Classic or superelastic (SE) archwires 0.014 and 0.016 orthodontic treatment
Study NCT05701956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over 5-10 seconds) before endovascular thrombectomy
Study NCT05701956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular thrombectomy
Description: The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.
Study NCT05701956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Description: The choice of endovascular thrombectomy strategy will be made by the treating neurointerventionist. All thrombectomy devices for endovascular treatment, which are approved by CFDA for this purpose, are allowed in the trial.
Study NCT06192147 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein restricted diet combined with vitamin D intervention
Description: On the basis of conventional treatment, a protein restricted diet combined with vitamin D intervention plan is given
Study NCT05833113 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~The control group will also receive the TENS-pants electrodes, connected to TENS treatment. In the placebo-TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. However, the TENS treatment to the control group will be set so that no electricity will reach the patient.~A multimodal analgesia regimen will be applied postoperatively
Study NCT05833113 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~In the TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. TENS device will be applied 4 times a day with treatment periods of 30 minutes.~A multimodal analgesia regimen will be applied postoperatively
Study NCT06234202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Sleeve
Description: Pitchers will wear a bioactive sleeve immediately post-game through overnight.
Study NCT06234202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Sleeve
Description: Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.
Study NCT05961306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SCID 5
Description: SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone.
Study NCT06641193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency-repetitive transcranial magnetic stimulation
Description: rTMS involves the repeated application of magnetic pulses to specific areas of the brain. These pulses are delivered using a coil placed on the scalp, which generates a magnetic field that induces electrical currents in the brain tissue.
Study NCT06641193 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The sham group receives 10 sessions of rTMS stimulation with a sham stimulation coil, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
Study NCT05587504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 1 and pronation level 1
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1.
Study NCT05587504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 1 and pronation level 2
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2.
Study NCT05587504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 2 and pronation level 1
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1.
Study NCT05587504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 2 and pronation level 2
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2.
Study NCT05533957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of different dosages of oxygen therapy
Description: To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
Study NCT04677556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Esogastric pressures measurement
Description: Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued.
Study NCT06523556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Given IV
Study NCT05967780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Patients with FHP receiving standard cardiac rehabilitation
Description: Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper \& lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.
Study NCT05967780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises
Description: The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital.
Study NCT05967780 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C: Patients without FHP receiving standard cardiac rehabilitation
Description: The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
Study NCT06523556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC
Study NCT06523556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06523556 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT06523556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study NCT05829291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: Alpha DaRT Applicators (the Alpha Needle Applicator, the Alpha Flex Applicator, and the Alpha Plant Applicator) and radioactive sources named Alpha DaRT Seeds - Ra-224 coated onto stainless steel tubes inserted into the tumor. Collectively, the Alpha DaRT Applicators and Seeds are referred to as the Alpha DaRT Device.
Study NCT05345379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single intervention
Description: Single intervention at the day of fixed orthodontic appliance bonding
Study NCT04959487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food support
Description: 1. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.
Study NCT04959487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling and education
Description: 2. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
Study NCT06494969 — intervention group
Intervention type: DEVICE
Intervention: Intraocular pressure measurement
Description: Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).
Study NCT05529459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention
Study NCT05529459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention
Study NCT06449651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nipocalimab
Description: Nipocalimab will be administrated intravenously.
Study NCT06449651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated intravenously.
Study NCT06288191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Description: Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
Study NCT06202651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure.